Nikolai Lomov

Dr. Nikolai Lomov

Lomonosov Moscow State University, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
NLNikolai Lomov
Nikolai Lomov
VVVladimir Viushkov
Vladimir Viushkov
APA. P. Petrenko
A. P. Petrenko
MSM. S. Syrkina
M. S. Syrkina
MRMikhail Rubtsov
Mikhail Rubtsov
— The CRISPR/Cas system is currently widely used for genome editing. The procedure of genome editing includes two necessary steps: (i) searching for the most effective guide RNA, and (ii)...

16 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
VVVladimir Viushkov
Vladimir Viushkov
NLNikolai Lomov
Nikolai Lomov
MRMikhail A. Rubtsov
Mikhail A. Rubtsov
Yegor VassetzkyYegor Vassetzky
Yegor Vassetzky
Over the years, our vision of the genome has changed from a linear molecule to that of a complex 3D structure that follows specific patterns and possesses a hierarchical organization. Currently, genomics is becoming “four-dimensional”: our attention is increasingly focused on the study of chromatin dynamics over time, in the fourth dimension. Recent methods for visualizing the movements of chromatin loci in living cells by targeting fluorescent proteins can be divided into two groups. The first group requires the insertion of a special sequence into the locus of interest, to which proteins that recognize the sequence are recruited (e.g., FROS and ParB-INT methods). In the methods of the second approach, “programmed” proteins are targeted to the locus of interest (i.e., systems based on CRISPR/Cas, TALE, and zinc finger proteins). In the present review, we discuss these approaches, examine their strengths and weaknesses, and identify the key scientific problems that can be studied using these methods.

17 October 2022 in Cancer Communications
Verified
Journal Article
Open access
ASAnna Shmakova
Anna Shmakova
NLNikolai Lomov
Nikolai Lomov
VVVladimir Viushkov
Vladimir Viushkov
TTTatyana Tsfasman
Tatyana Tsfasman
YKYana Kozhevnikova
Yana Kozhevnikova
Yegor VassetzkyYegor Vassetzky
Yegor Vassetzky

18 November 2020 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
NLNikolai Lomov
Nikolai Lomov
EZElena Zerkalenkova
Elena Zerkalenkova
SLSvetlana Lebedeva
Svetlana Lebedeva
VVVladimir Viushkov
Vladimir Viushkov
MRMikhail Rubtsov
Mikhail Rubtsov
Acute leukemias (ALs) are often associated with chromosomal translocations, in particular, KMT2A/MLL gene rearrangements. Identification or confirmation of these translocations is carried out by a number of genetic and molecular methods, some of which are routinely used in clinical practice, while others are primarily used for research purposes. In the clinic, these methods serve to clarify diagnoses and monitor the course of disease and therapy. On the other hand, the identification of new translocations and the confirmation of known translocations are of key importance in the study of disease mechanisms and further molecular classification. There are multiple methods for the detection of rearrangements that differ in their principle of operation, the type of problem being solved, and the cost-result ratio. This review is intended to help researchers and clinicians studying AL and related chromosomal translocations to navigate this variety of methods. All methods considered in the review are grouped by their principle of action and include karyotyping, fluorescence in situ hybridization (FISH) with probes for whole chromosomes or individual loci, PCR and reverse transcription-based methods, and high-throughput sequencing. Another characteristic of the described methods is the type of problem being solved. This can be the discovery of new rearrangements, the determination of unknown partner genes participating in the rearrangement, or the confirmation of the proposed rearrangement between the two genes. We consider the specifics of the application, the basic principle of each method, and its pros and cons. To illustrate the application, examples of studying the rearrangements of the KMT2A/MLL gene, one of the genes that are often rearranged in AL, are mentioned.

Verified
Journal Article
Open access
PDF file
NLNikolai Lomov
Nikolai Lomov
VVVladimir Viushkov
Vladimir Viushkov
SUSergey V. Ulianov
Sergey V. Ulianov
AGAlexey A. Gavrilov
Alexey A. Gavrilov
DADaniil A. Alexeyevsky
Daniil A. Alexeyevsky
MRMikhail Rubtsov
Mikhail Rubtsov
Topoisomerase inhibitors are widely used in cancer chemotherapy. However, one of the potential long-term adverse effects of such therapy is acute leukemia. A key feature of such therapy-induced acute myeloid leukemia (t-AML) is recurrent chromosomal translocations involving AML1 (RUNX1) or MLL (KMT2A) genes. The formation of chromosomal translocation depends on the spatial proximity of translocation partners and the mobility of the DNA ends. It is unclear which of these two factors might be decisive for recurrent t-AML translocations. Here, we used fluorescence in situ hybridization (FISH) and chromosome conformation capture followed by sequencing (4C-seq) to investigate double-strand DNA break formation and the mobility of broken ends upon etoposide treatment, as well as contacts between translocation partner genes. We detected the separation of the parts of the broken AML1 gene, as well as the increased mobility of these separated parts. 4C-seq analysis showed no evident contacts of AML1 and MLL with loci, implicated in recurrent t-AML translocations, either before or after etoposide treatment. We suggest that separation of the break ends and their increased non-targeted mobility—but not spatial predisposition of the rearrangement partners—plays a major role in the formation of these translocations.

1 January 2019 in Molekulârnaâ biologiâ
Verified
Journal Article
Closed access
NLNikolai Lomov
Nikolai Lomov
ВВВ. С. Вьюшков
В. С. Вьюшков
АПА. П. Петренко
А. П. Петренко
МСМ. С. Сыркина
М. С. Сыркина
МРМ. А. Рубцов
М. А. Рубцов
The CRISPR/Cas system is currently widely used for genome editing. The procedure of genome editing includes two necessary steps: (i) searching for the most effective guide RNA, and (ii) analyzing clones for presence of the desired mutation. This review presents the methods used to assess the efficiency of the CRISPR/Cas system and to confirm mutation in the target locus and discusses their advantages and disadvantages. It aims to provide information that could help researchers to choose a technique most appropriate for their specific tasks and available resources.